Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

Quince Therapeutics will end the development of its lead asset, a treatment for the neurodegenerative disorder ataxia-telangiectasia, after a pivotal Phase 3 trial failed to meet its expected outcomes ...

Topline results show eDSP failed to significantly improve RmICARS scores in ataxia-telangiectasia patients compared with placebo in the NEAT trial.

STEMart announces the expansion of its genetic toxicology capabilities with the In Vivo Rat Micronucleus Test services.

A shortage of blood donations in Germany could have dramatic consequences. The situation was critical in mid-January. DW's ...

A nose-to-brain drug delivery approach leverages neural pathways to achieve high brain exposure with low systemic levels, offering a non-invasive alternative to transporter-based BBB strategies for ...

In A Nutshell Researchers discovered that chemical brake signals in the blood control when certain immune cells stop ...

THE electrical conductivity of an electrolyte is determined by its ion concentration. The effect of dispersed solid particles of a comparatively low conductance, such as proteins, can be taken into ...

Investing.com -- Quince Therapeutics Inc (NASDAQ:QNCX) stock plunged 13.7% on Thursday after the company announced that its pivotal Phase 3 NEAT clinical trial for Ataxia-Telangiectasia (A-T) failed ...

Quince Therapeutics’ lead asset eDSP failed to meet the primary or secondary endpoints in the pivotal NEAT trial.

Quince Therapeutics, Inc. , a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation ...

The company announced that it has decided to cease clinical development of its lead asset dexamethasone sodium phosphate ...